Published in Psychopharmacology (Berl) on January 01, 1991
Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. J Med Toxicol (2014) 1.10
Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol (1992) 0.83
Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nucl Med Biol (2010) 0.81
In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. Eur J Nucl Med Mol Imaging (2009) 0.79
In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy. PLoS One (2014) 0.79
Therapeutic drug monitoring in saliva. Clin Pharmacokinet (1978) 2.66
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther (2007) 1.47
Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth (2005) 1.44
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther (1992) 1.41
Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth (2006) 1.41
Modeling and simulation at the interface of nonclinical and early clinical drug development. CPT Pharmacometrics Syst Pharmacol (2013) 1.40
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica (1979) 1.37
A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther (2010) 1.30
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol (1982) 1.13
Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. Clin Pharmacol Ther (2011) 1.12
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther (1998) 1.11
Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm. Clin Pharmacokinet (1997) 1.11
Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) (2005) 1.06
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol (1988) 1.04
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther (1988) 1.02
Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. J Pharmacol Exp Ther (1984) 1.00
Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet (1992) 0.99
Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit (1994) 0.99
From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs. Clin Pharmacol Ther (2009) 0.99
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship. Clin Pharmacol Ther (1985) 0.99
Partial agonism of theophylline-7-riboside on adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.99
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther (1998) 0.99
Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. Eur J Pharmacol (1996) 0.98
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther (1987) 0.98
Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther (1988) 0.97
Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res (1998) 0.97
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther (1997) 0.96
Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat. J Pharmacol Exp Ther (1997) 0.96
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther (1999) 0.96
Critical factors of intracerebral microdialysis as a technique to determine the pharmacokinetics of drugs in rat brain. Brain Res (1994) 0.95
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. J Pharmacokinet Biopharm (1990) 0.95
Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther (1991) 0.95
Quantification of the EEG effect of midazolam by aperiodic analysis in volunteers. Pharmacokinetic/pharmacodynamic modelling. Clin Pharmacokinet (1990) 0.94
Negligible sublingual absorption of nifedipine. Lancet (1987) 0.93
Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol (2007) 0.93
A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. Am J Physiol Regul Integr Comp Physiol (2001) 0.93
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther (1986) 0.92
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. J Pharmacol Exp Ther (1999) 0.92
A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol (1997) 0.92
Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. Pharmacology (1981) 0.92
The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology (1999) 0.90
Determination of the threshold for convulsions by direct cortical stimulation. Epilepsy Res (1989) 0.90
Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. Br J Clin Pharmacol (1999) 0.90
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol (1991) 0.89
A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokinet Biopharm (1991) 0.89
Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther (1984) 0.89
A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin Pharmacol Ther (2000) 0.89
Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats. Br J Pharmacol (1995) 0.88
The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. Br J Clin Pharmacol (1989) 0.88
From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol (2012) 0.88
Rectal bioavailability of lidocaine in man: partial avoidance of "first-pass" metabolism. Clin Pharmacol Ther (1979) 0.88
Repeated microdialysis perfusions: periprobe tissue reactions and BBB permeability. Brain Res (1995) 0.87
From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther (2009) 0.87
Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm (1999) 0.87
From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II-Sensitivity to Physiological and Physicochemical Properties. CPT Pharmacometrics Syst Pharmacol (2012) 0.87
Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach. J Pharm Sci (2009) 0.86
High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J Chromatogr (1993) 0.86
Increased sensitivity to the anesthetic effect of phenobarbital in aging BN/BiRij rats. J Pharmacol Exp Ther (1992) 0.86
Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline. Br J Pharmacol (1995) 0.86
Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system. Clin Pharmacol Ther (1988) 0.86
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol (2008) 0.86
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J Med Chem (1995) 0.86
Long-term sedation with propofol 60 mg ml(-1) vs. propofol 10 mg(-1) ml in critically ill, mechanically ventilated patients. Acta Anaesthesiol Scand (2004) 0.86
Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. Eur J Clin Pharmacol (2000) 0.85
Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. J Pharmacokinet Biopharm (1988) 0.85
Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br J Pharmacol (2007) 0.85
A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. J Pharm Sci (1991) 0.85
Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats. Br J Pharmacol (1998) 0.85
The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system. J Pharmacokinet Biopharm (1989) 0.85
Assay of 3-carboxy-antipyrine in urine by capillary gas chromatography with nitrogen selective detection. Some preliminary results in man. Pharmacology (1979) 0.85
Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain. Br J Pharmacol (1995) 0.84
Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. J Pharm Sci (1999) 0.84
Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". J Ethnopharmacol (2008) 0.84
Analysis of the relationship between age and treatment response in migraine. Cephalalgia (2009) 0.84
Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats. J Pharmacol Exp Ther (2003) 0.83
The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. Br J Clin Pharmacol (1988) 0.83
Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol (1992) 0.83
PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats. Br J Pharmacol (2013) 0.83
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. J Pharmacol Exp Ther (1997) 0.83
Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother (1996) 0.83
Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther (1997) 0.83
Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. Br J Clin Pharmacol (1980) 0.82
Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass. Braz J Med Biol Res (1997) 0.82
Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharm Res (1991) 0.82
Iontophoretic delivery of apomorphine. I: In vitro optimization and validation. Pharm Res (1997) 0.82
Cutaneous side-effects of transdermal iontophoresis with and without surfactant pretreatment: a single-blinded, randomized controlled trial. Br J Dermatol (2005) 0.82
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. J Pharmacol Exp Ther (1995) 0.82
The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res (1995) 0.82
A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J Pharmacokinet Biopharm (1999) 0.82